Landmark trial ๐๐
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial - The Lancet Gastroenterology & Hepatology
Early is key in CD. Next frontier is to catch the disease before diagnosis!
Early Biologic Treatment Decreases Risk of Surgery in Crohn's Disease but not in Ulcerative Colitis: Systematic Revโฆ
- Took years to recruit bionaive patients !
- Rationale combination needed to be transformative
- Bayesian analysis should be used more for POC studies
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)
Urgent need to understand more about diet and ibd as shown by this โheat mapโ of โgoodโ and โbadโ food according to different recommended diets !!!
In a nutshell it is a mess ๐คชThis is from editorial in Gastroenterology that we wrote with Joao Sabino from Leuven !!!!
Four NIH K awardees in our GE division in record time !
Youth is blossoming at Sinai.Research in predictors of response of IBD therapy, host microbe interactions, early life risk factors for Ibd and role of wearable device. More coming soon ! @ManasiAgrawalMD @ryanungaro123
Was thinking that complications of CD mostly occur as a consequence of disease progression from diagnosis.
Not only !!!!
Preclinical Serological Signatures are Associated with Complicated Crohn's Disease Phenotype at Diagnosis.
